KR20230165782A - 수술 후 회복을 위한 오렉신 2 수용체 작용제의 용도 - Google Patents

수술 후 회복을 위한 오렉신 2 수용체 작용제의 용도 Download PDF

Info

Publication number
KR20230165782A
KR20230165782A KR1020237033928A KR20237033928A KR20230165782A KR 20230165782 A KR20230165782 A KR 20230165782A KR 1020237033928 A KR1020237033928 A KR 1020237033928A KR 20237033928 A KR20237033928 A KR 20237033928A KR 20230165782 A KR20230165782 A KR 20230165782A
Authority
KR
South Korea
Prior art keywords
compound
methyl
administration
anesthesia
sedation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033928A
Other languages
English (en)
Korean (ko)
Inventor
하루히데 기무라
모토히사 스즈키
제임스 크로니컨
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20230165782A publication Critical patent/KR20230165782A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237033928A 2021-04-02 2022-04-01 수술 후 회복을 위한 오렉신 2 수용체 작용제의 용도 Pending KR20230165782A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170211P 2021-04-02 2021-04-02
US63/170,211 2021-04-02
PCT/IB2022/053085 WO2022208478A1 (en) 2021-04-02 2022-04-01 Use of an orexin 2 receptor agonist for post operation recovery

Publications (1)

Publication Number Publication Date
KR20230165782A true KR20230165782A (ko) 2023-12-05

Family

ID=81326367

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033928A Pending KR20230165782A (ko) 2021-04-02 2022-04-01 수술 후 회복을 위한 오렉신 2 수용체 작용제의 용도

Country Status (12)

Country Link
US (1) US20240165092A1 (https=)
EP (1) EP4313045A1 (https=)
JP (1) JP2024511676A (https=)
KR (1) KR20230165782A (https=)
CN (1) CN117396203A (https=)
AU (1) AU2022252108A1 (https=)
BR (1) BR112023020104A2 (https=)
CA (1) CA3215906A1 (https=)
CO (1) CO2023013001A2 (https=)
MX (1) MX2023011669A (https=)
TW (1) TW202304437A (https=)
WO (1) WO2022208478A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド D―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
US11034700B2 (en) 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7413261B2 (ja) 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
EP3896060B1 (en) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3154321A1 (en) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
1: Sleep Med Rev 11 (2007) 35-46
2: Pharmacol Rev 61 (2009) 162-176
3: Cell 92 (1998) 573-585

Also Published As

Publication number Publication date
WO2022208478A1 (en) 2022-10-06
CO2023013001A2 (es) 2023-10-30
CN117396203A (zh) 2024-01-12
US20240165092A1 (en) 2024-05-23
CA3215906A1 (en) 2022-10-06
JP2024511676A (ja) 2024-03-14
AU2022252108A1 (en) 2023-10-05
BR112023020104A2 (pt) 2023-11-14
MX2023011669A (es) 2023-10-18
TW202304437A (zh) 2023-02-01
EP4313045A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP6931019B2 (ja) 多発性硬化症を処置するためのs1p受容体モジュレーター
JP2025125557A (ja) 心理療法を補助するためのmdmaプロドラッグ
JP5907975B2 (ja) 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ
US20120101073A1 (en) Novel Method For Treating Breathing Disorders or Diseases
WO2012166909A1 (en) Compositions and methods for treating breathing control disorders or diseases
JP2022547604A (ja) 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用
RU2011146032A (ru) Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности
US20210145785A1 (en) Compositions and methods for stimulating ventilatory and/or respiratory
CN1738611A (zh) 用作抗偏头痛剂的α-氨基酰胺衍生物
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
KR20230165782A (ko) 수술 후 회복을 위한 오렉신 2 수용체 작용제의 용도
JP5042625B2 (ja) 抗炎症剤として有用なα−アミノアミド誘導体
EA033769B1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
WO2022004788A1 (ja) 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
JPH08504203A (ja) パーキンソン病およびその進行を治療する薬剤の製造のためのイダゾキサンおよびその誘導体の使用
JPH09500375A (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
JP5198852B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
WO2022190060A1 (en) An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
US20250262181A1 (en) Compositions and methods for stimulating ventilatory and/or respiratory
JP2021505668A (ja) 併用療法(睡眠障害およびcns障害)において使用するためのnmda受容体モジュレーター(ラパスチネル)の組合せ
EP4719397A1 (en) Use of an orexin 2 receptor agonist for improving respiratory function during sleep
CN110381934A (zh) 用于治疗睡眠呼吸障碍(sdb)的l-pag衍生物
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000